Quest for the right Drug
גנטמיצין ב.בראון 3 מ"ג/מ"ל GENTAMICIN B. BRAUN 3 MG/ML (GENTAMICIN AS SULFATE)
תרופה במרשם
תרופה בסל
נרקוטיקה
ציטוטוקסיקה
צורת מתן:
תוך-ורידי : I.V
צורת מינון:
תמיסה לאינפוזיה : SOLUTION FOR INFUSION
עלון לרופא
מינוניםPosology התוויות
Indications תופעות לוואי
Adverse reactions התוויות נגד
Contraindications אינטראקציות
Interactions מינון יתר
Overdose הריון/הנקה
Pregnancy & Lactation אוכלוסיות מיוחדות
Special populations תכונות פרמקולוגיות
Pharmacological properties מידע רוקחי
Pharmaceutical particulars אזהרת שימוש
Special Warning עלון לרופא
Physicians Leaflet
Adverse reactions : תופעות לוואי
4.8 Undesirable effects Under certain conditions gentamicin shows ototoxic and/or nephrotoxic effects. Renal impairment is commonly observed in patients treated with gentamicin and is usually reversible upon withdrawal of the drug. In most cases nephrotoxicity is associated with an excessively high dosage or prolonged treatment, pre-existing renal abnormalities or associated with other substances reported to be nephrotoxic. The adverse reactions considered at least possibly related to treatment are listed below by body system organ class and absolute frequency. Frequencies are defined as very common (1/10); common (>1/100 to <1/10); uncommon (>1/1000 to <1/100); rare (>1/10 000 to <1/1000); very rare (<1/10 000), not known (frequency cannot be estimated from the available data). System Organ Common Uncommon Rare (>1/10 000 Very rare (≤1/10 Frequency not Class (≥1/100 to (>1/1 000 to to ≤1/1 000) 000) known <1/10) <1/100) (cannot be estimated from the available postmarketing data) Infections and Superinfection (with infestations gentamicin-resistant germs), pseudomembranous colitis (see also section 4.4)1 Blood and Dyscrasia Thrombocytopaenia, lymphatic reticulocytopaenia, system leukopaenia, disorders eosinophilia, granulocytopaenia, anaemia Immune system Hypersensitivity disorders reactions of varying severity, ranging from rash and itching, drug fever to severe acute hypersensitivity reactions (anaphylaxis), up to anaphylactic shock Metabolism and Hypokalaemia, Hypophosphataemia nutrition hypocalcaemia, disorders hypomagnesaemia, pseudo-Bartter syndrome in patients treated with high doses over a long period (more than 4 weeks), loss of appetite, weight loss Psychiatric Confusion, disorders hallucinations, mental depression Nervous system Polyneuropathies, Encephalopathy, disorders peripheral convulsions, paraesthesias neuromuscular blockage, dizziness, balance disorder, headache, (see also section 4.4) Eye disorders Visual disorders Ear and Vestibular damage, Irreversible hearing labyrinth hearing loss, Meniére`s loss, deafness disorders disease, tinnitus, vertigo (see also section 4.4) Vascular Hypotension, disorders hypertension Gastrointestinal Vomiting, nausea, disorders salivation increased, stomatitis Hepatobiliary Aspartate disorders aminotransferase (AST) increased, Alanine aminotransferase (ALT) increased, alkaline phosphatase (ALP) increased, reversible increase of serum bilirubin (all reversible) Skin and Allergic skin Skin reddening Toxic epidermal subcutaneous exanthema necrolysis2, Stevens- tissue disorders Johnson syndrome2, Erythema multiforme2, Alopecia Musculoskeletal Muscle pain Amyostasia and connective (myalgia) tissue disorders Renal and Renal Blood urea Acute renal failure, urinary function nitrogen increased hyperphosphaturia, disorders impairment (reversible) aminoaciduria, Fanconi-like syndrome in patients treated with a prolonged course of high-dose, see also section 4.4. General Increased body Pain at injection site disorders and temperature administration site conditions 1 Usually in these cases other antibiotics are also involved. 2 May occur as hypersensitivity reactions. Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Any suspected adverse events should be reported to the Ministry of Health according to the National Regulation by using an online form https://sideeffects.health.gov.il
שימוש לפי פנקס קופ''ח כללית 1994
לא צוין
תאריך הכללה מקורי בסל
01/01/1995
הגבלות
תרופה מוגבלת לשימוש בבתי חולים או אשפוז יום
מידע נוסף